Guggenheim Says Bausch Health Companies (BHC) Sell-Off 'Overdone'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Cowen Defends Bausch Health Companies (BHC); 'Add Here'
February 19, 2020 11:37 AM ESTCowen analyst Ken Cacciatore reiterated an Outperform rating and $40.00 price target on Bausch Health Companies (NYSE: BHC), saying there is no change to the thesis and investors should add here.
The analyst commented, "Q4 revs were slightly above the Street, while earnings... More
Bausch Health Co. Inc. (BHC) Posts Q4 Adjusted EBITDA of $898 Million, Revs Beat
February 19, 2020 7:02 AM ESTBausch Health Co. Inc. (NYSE: BHC) reported Q4 Adjusted EBITDA of $898 Million. Revenue for the quarter came in at $2.28 billion versus the consensus estimate of $2.2 billion.
GUIDANCE:
Bausch Health Co. Inc. sees FY2020 revenue of $8.65-8.85 billion, versus the consensus of... More
